The heart and androgens;Cœur et androgènes

Annales d'Endocrinologie

Volumn 65, Issue 2, 2004, Pages 163-170

  Smeets, L ^a   Legros, J J ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Androgens; Coronary heart disease; Heart failure; Lipid profile; Testosterone

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; CYTOKINE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 6; TESTOSTERONE; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR; LIPID;

CARDIOVASCULAR SYSTEM; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY DILATATION; CORONARY ARTERY DISEASE; HEART FAILURE; HEART FUNCTION; HEART HYPERTROPHY; HEART MUSCLE CELL; HOMEOSTASIS; INFLAMMATION; LIPID ANALYSIS; REGULATORY MECHANISM; REVIEW; TESTOSTERONE BLOOD LEVEL; VASCULAR RESISTANCE; BLOOD; HEART; HUMAN; MALE; PATHOPHYSIOLOGY; PHYSIOLOGY; SEXUAL BEHAVIOR;

ANDROGENS; CORONARY DISEASE; HEART; HUMANS; INFLAMMATION; LIPIDS; MALE; SEXUAL BEHAVIOR;

EID: 4444366402     PISSN: 00034266     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0003-4266(04)95664-8     Document Type: Article

References (61)

1. Araneo BA, Dowell T, Diegel M, Daynes RA. Dihydrotestosterone exerts a depressive influence on the production of interleukin 'V-interferon, but not by activated murine T cells. Blood 1991; 3: 688-699.
2. Beer NA, Jakubowicz DK, Madd DW, et al. Dehydroepiandrosterone reduces plasmaplasminogen activator inhibitor type 1 and tissue plasma activator antigen in men. Am J Med Sci 1996; 311: 205-210.
3. Ben-Nathan O, Padgett DA, Loria RM. Androstenediol and dehydroepiandrosterone protect mice against lethal bacterial infection and lipopolysaccharide toxicity. J Med Microbiol 1999; 48: 425-431.
4. Campbell S, Farb A, Weber KT, et al. Pathologic remodelling of the myocardium in a weightlifter taking anabolic steroids. Blood press 1993; 2: 213-216.
5. Chao TC, Van Alten P, Greager JA, Walter RJ. Steroid sex hormones regulate the release of tumor necrosis factor by macrophages. Cell Immunol 1995; 160: 43-49.
6. Coats A. Origin of symptoms in patients with cachexia with special references to weakness and shortness. Int J cardiol 2002; 85: 133-139.
7. Dalal M, Kim S, Voskuhl RR. Testosterone therapy ameliorates experimental autoimmune encephalomyelitis and induces a T helper 2 bias in the autoantigen-specific T lymphocyte response. J Immunol 1997; 159: 3-6.
8. English KM, Jones RD, Jones RH, et al. Testosterone acts as a coronary vasodilatator by a calcium channel antagonist action. J endocrinol Invest 2002; 25: 455-458.
9. English KM, Mandour O, Steeds RP, et al. Men with coronary artery disease have a lower levels of testosterone than those with normal coronary angiograms. Eur Heart J 2000; 21: 890-895.
10. English KM, Steeds RP, Jones TH, Diver MJ, Channer KS. Low dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina. Circulation 2000; 102: 1906-1911.
11. Feldman HA, Johannes CB, Araujo AB, Mohr BA, Longcope C, McKinlay JB. Low dehydroepiandrosterone and ischemic heart disease in middle-aged men: prospective results from the Massachusetts Male Aging Study. Am J Epidemiol 2001; 153: 79-89.
12. Friedl R, Brunner M, Moeslinger T, Spieckermann. Testosterone inhibits expression of inductible nitric oxide synthase in murine macrophages. Life sci 2000; 68: 417-429.
13. Fujimoto R, Morimoto I, Morita E. Androgens receptors, 5alpha reductase activity and androgens-dependent proliferation of vacular smooth muscle cells. J steroid Biochem Mol Biol 1994; 50: 69-174.
14. Gaillard RC. Effects of gonadectomy and sex hormone therapy on the endotoxin-stimulated hypothalamo-pituitary-adrenal axis: evidence for a neuroendocrin-immunological sexual dimorphism. Endocrinology 1992; 131: 2430-2436.
15. Gregory CW, He B, Wilson EM. The putative androgen receptor: A form results from in vitro proteolysis. J mol Endocrinol 2001; 27: 309-319.
16. Hamm L. Testosterone propionate in the treatment of angina pectoris. J Clin Endocrinol 1942; 2: 325-328.
17. Herman Sm, Robinson JT, Mc credie RJ. Androgens deprivation is asscociated with enhanced endothelium-dependent dilatation in adult men. Artherioscler Tromb vasc biol 2002; 17: 2004-2009.
18. Higashiura K, Marthur RS. Gender-related differences in androgen regulation of thromboxane A2 receptors in rat aortic smooth muscle cells. J cardiovasc pharmacol 1991; 29: 311-315.
19. Hofbauer LC, Ten RM, Khosla S. The anti-androgen hydroxyflutamide and androgens inhibit interleukin-6 production by an androgen-responsive human osteoblastic cell line. J Bone Miner Res 1999; 14: 1330-1337.
20. Holm P, Andersen HL, Arroe G. Gender gap in aortic cholesterol accumulation in cholesterol-clamped rabbits: role of endothelium and mononuclear-endothelial cell interaction. Circulation 1998; 98: 2731-2737.
21. Jaffe MD. Effect of testosterone cypionate on postexercise ST segment depression. Br Heart J 1997; 39: 1217-1222.
22. Jesper G, Susanne L, Borch-Johnsen K. Cardiovascular risk factors in men: the role of gonadal steroids and sex hormone-binding globulin. Metabolism 2001; 50: 882-888.
23. Jesse RL, Loesser K, Eich DM, et al. Dehydroepiandrosterone inhibits human platelet aggregation in vitro and in vivo. Ann N Y Acad Sci 1995; 774: 281-290.
24. Kanda N, Tsuchida T, Tamaki K. Testosterone inhibits immunoglobulin production by human peripheral blood mononuclear cells. Clin Exp Immunol 1996; 106: 410-415.
25. Khalil A, Lehoux JG, Wagner RJ, et al. Dehydroepiandrosterone protects Iow low density lipoproteins against peroxidation by free radicals produced by gammma-radiolys of ethanol-water mixture. Atherosclerosis 1998; 136: 99-107.
26. Kimura M, Tanaka 5-1, Yamada Y, Kiuchi Y, Yamakawa T, Sekihara H. Dehydroepiandrosterone decreases serum tumor necrosis factor-a and restores insulin sensitivity: independent effect from secondary weight reduction in genetically obese Zucker fatty rats. Endocrinology 1998; 139: 3249-3253.
27. Lesser MA. Testosterone propionate therapy in one hundred cases of angina pectoris. J Clin Endocrinol 1946; 6: 549-557.
28. Levine SA, Likoff WB. The therapeutic value of testosterone propionate in angina pectoris. N Engl J Med 1943; 229: 770-772.
29. Ling S, Dai A, Williams MR. Testosterone enhance apoptosis-related damage in human vascular endothelial cells. Endocrinology 2002; 143: 1119-1125.
30. Loukorvaara M, Carson M, Adlercreutz H. Regulation of production and secretion of sex-hormone binding globulin in HepG2 cell culture by hormones and growth factors. J clin Endocrinol Metab 1995; 80: 160-164.
31. Malhotra A, Buttrick, Scheurer J, et al. Effects of sex hormones on development of physiological and pathological hypertrophy in male and female rat. Am J physiol 1990; 25: 866-871.
32. Marsh JD, Lehma, nn MH, Rictchie RH, et al. Androgen receptors mediate hypertrophy in cardiac myocytes. Circulation 1998; 98: 256-261.
33. McCrohon JA, Death AK, Nakla S, et al. Androgen receptor expression is greater in macrophages from male than from female donnors. A sex difference with implications for atherogenesis. Circulation 2000; 101: 224-226.
34. McGratj KCY, Sader MS, Nakla S, et al. Androgens up regulate VCAM-1 in a gender specific manner via NFKB-dependent pathway in human endothelial cells. Program of the 51 st annual scientific meeting of the cardiac society of australia and New zealand, Adelaide, Australia 2003 (abstract).
35. Melchert R, Herron TJ, Welder AA. The effect of anabolic-androgenic steroids on primary myocardial cell cultures. Med sci sport s Exerc 1992; 24: 206-212.
36. Morano I, Gerstener J, Ruegg JC, Ganten U, Ganten D. Regulation of myosin heavy chain expression in the hearts of hypertensive rats by testosterone. Circ Res 1996; 66: 1585-1590.
37. Morris P, Pugh PJ, Hall J, et al. The relation ship between smoking, statin therapy and testosterone in men with coronary artery disease. Endocrine Abstracts 2002: 248.
38. Noirhomme P, Jaquet L, Underwood M, El Khoury G, Goenen M, Dion R. The effect of chronic mechanical circulatory support on neuroendocrine activation in patients with end-stage heart failure. Eur J Cardiothorac Surg 1999; 16: 63-67.
39. O'Agostino P, Milano S, Barbera C, et al. Sex hormones modulate inflammatory mediators produced by macrophages. Ann N Y Acad Sci 1999; 876: 426-429.
40. Padgett DA, Loria RM. Endocrine regulation of murine macrophage function: effects of dehydroepiandrosterone, androstenediol, and androstenetriol. J Neuroimmunol 1998; 84: 61-68.
41. Pugh PJ, English KM, Jones TH, Channer KS. Testosterone: a natural tonic for the faling heart? QJM 2000; 93: 689-694.
42. Porsova D, Sulcova J. Do DHEA/DHEAS play a protective role in coronary heart disease? Physiol Res 2000; 49: 43-56.
43. Pugeat M, moulin P, Cousin P, et al. Interrelations between sex-hormone binding globulin, plasma lipoproteins and cardiovascular risks. J Steroid Biochem Mol Biol 1995; 53: 567-572.
44. Raitakari OT, Celemajer. Flow-mediated dilatatation. Br J Clin pharmacol 2000; 50: 397-404.
45. Rosano GMC, Leonardo F, Pagnotta P, et al. Acute anti-ischemic effect of testosterone in men with coronary artery disease. Circulation 1999; 99: 1666-1670.
46. Schaible TF, Malhotral A, Ciambrone G, et al. The effect of gonadectomy on left ventricular function and cardiac contractile proteins in male and female rats. Circ Res 1984; 54: 38-49.
47. Scheuer J, Malhotra A, Schaible TF, Capasso J. Effects of gonadectomy and hormonal replacement on rat hearts. Circ Res 1987; 61: 12-19.
48. Seta V, Shan K, Bozkurt B, Oral H, Mann DI. Basic; mechanisms in heart failure: the cytokine hypothesis. J Card Fail 1996; 2: 243-249.
49. Shapiro J, Christiana J, Frishman W. Testosterone and other anabolic steroids as cardiovascular drugs. Am J Ther 1999; 6: 167-174.
50. Sigler LH, Tulgan J. Treatment of angina pectoris by testosterone propionate. N Y State J Med 1943; 43: 1424-1428.
51. Silver MD. Cardiovascular pathology. Deuxième edition. Churchill. Livingstone: New York, 1991.
52. Stearns El, Mac Donnel JA, Kaufman BJ, et al. Declining testicular function with age. Am J Med 1974; 57: 761.
53. Straub RH, Konecna L, Hrach S, Rothe G, Kreutz M, Scholmerich j, Falk W, Lang B. Serum dehydroepiandrosterone (DHEA) and DHEA sulfate are negatively correlated with serum interleukin-6and DHEA inhibits II-6 secretion from mononuclear cells in man in vitro: possible link between endocrinosenescence and immunosenescence. J Clin Endocrinol Metab 1998; 83: 2012-2017.
54. Tappler B, Katz M. Pituitary-gonadal dysfunction in low-output cardiac failure. Clin Endocrinol 1979; 10: 219-226.
55. The world health report 2002 Geneva. world health organisation.
56. Thum T, Borlak J. Testosterone, cytochrome P450 and cardiac hypertrophy. Faseb J 2002; 16: 1537-1549.
57. Walker TC. Use of testosterone propionate and estrogenic-substance in treatment of essential hypertension, angina pectoris and peripheral vascular disease. J Clin Endocrinol 1942; 2: 560-568.
58. Webb CM, Adamson DL, De Zeigler D, Collins P. Effect of acute testosterone on myocardial ischaemia in men with coronary artery disease. Am J Cardiol 1999; 83: 437-439.
59. Webb CM, Mc Neill JG, Hayward CS, et al. Effect of testosterone on coronary vasomotor regulation in men with coronary heart desease. Circulation 1999; 100: 1690-1696.
60. Wu S-Z, Weng X-Z. Therapeutic effects of an androgenic preparation on myocardial ischemia and cardiac function in 62 elderly male coronary heart disease patients. Chin Med J 1993; 106: 415-418.
61. Yoshimura M, Moriyama Y, Yasue H, et al. The plasma levels of DHEAS are decreased in patient with chronic heart failure in proportion to severity. J Clin Endocrinol Metab 2000; 85: 1834-1840.